Hyperactivity

...ba href=/hyperactivity/a/b disorder should not have to carry the government's strongest warning about potential cardiovascular and psychiatric risks, a federal advisory panel says.Instead of having the ‘‘black-box'' warnings, the drug labels should caution users about possible dangers in plain language that they can understand, the Food and Drug Administration pediatric advisory committee recommended Wednesday.By rejecting the black-box warnings in a consensus decision, the FDA advisers broke with another committee that voted just last month to include them on some ADHD drugs.

The FDA was poised Wednesday to follow the latest recommendations.‘‘I think we are likely to follow them, yes,'' Dr.

Robert Temple, director of the FDA's office of medical policy, said.Any updated language may not appear on labels until pharmaceutical companies begin using a recently adopted format, something that could take several years.

And the FDA may yet require black-box warnings on stimulants to treat ADHD that would alert adults to increased risk of heart attacks, strokes and other similar problems, Temple said.

Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions Inc., a prescription drug benefit program manager.Psychiatrists and others had urged the committee to move cautiously before recommending strengthened warnings associated with the drugs.In February, the FDA's Drug Safety and Risk Management advisory committee voted ...

...ba href=/hyperactivity/a/b disorder should bear the strongest type of warning of the potential cardiovascular and psychiatric risks they pose.

The consensus move by the Food and Drug Administration's pediatric advisory committee leaves in doubt whether the agency will require "black-box" labels on the drugs, which include Ritalin.

The panel, in simply recommending easier-to-understand language on the labels, broke with another committee that recommended that the drugs include the more dire warnings.

The pediatric advisory committee, without voting, did recommend adding more information to the labels for the benefit of doctors, patients and parents.

"I wouldn't use the word tougher, panel chairman Dr.

Robert Nelson said.

"Clearer." Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions Inc., a prescription-drug-benefit program manager.

Copyright © 2006, Orlando Sentinel Terms of Service © 2006 Orlando Sentinel Communications ...

...ba href=/hyperactivity/a/b disorder should not carry strong “black-box” warnings about potential cardiovascular and psychiatric risks.

Rather, the Food and Drug Administration pediatric advisory committee recommended that the drug labels include warning language written so people can understand it.

“I wouldn’t use the word ‘tougher,’ said panel chair Dr.

Robert Nelson, of the Children’s Hospital of Philadelphia.

“ ‘Clearer.’ ” By rejecting the black-box warnings in a consensus decision, the advisory panel broke with another committee that voted just last month to include them on some ADHD drugs.

The FDA was poised Wednesday to follow the more recent recommendations.

“I think we are likely to follow them, yes,” said Dr.

Robert Temple, director of the FDA’s office of medical policy, following the meeting.

Any updated language may not appear on labels until pharmaceutical companies begin using a recently adopted format, something that could take several years.

And the FDA may yet require black-box warnings on stimulants to treat ADHD that would alert adults to increased risk of heart attacks, strokes and other similar problems, Temple said.

Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions, a prescription drug benefit program manager.

Psychiatrists and others had urged the committee to move cautiously before recommending strengthened warnings associated with the drugs.

Earlier Wednesday, FDA officials say patients and doctors sho...